MedInCell Stock Up 2.85% at €25.22, Challenging Technical Resistance
The Montpellier-based biotech regains momentum in the mid-afternoon, following the CAC 40 which is up by 0.49% during the session. The stock is approaching a technical threshold observed for several weeks, just over a month before the annual results are published.
The Stock Approaches the €25.12 Threshold
MedInCell gains 2.85% to €25.22 during the session, after closing the previous day at €24.52. This movement largely offsets Monday's decline, bringing the weekly performance to nearly 6%. The price is immediately in contact with the resistance at €25.12, identified by market data. It also flirts with the upper limit of the Bollinger Bands, set at €25.61, placing the stock at the high end of its short-term technical range. The RSI at 56 remains in a neutral zone, without a marked overbought signal. The stock also moves back above its 200-day moving average (€24.23), a configuration it had briefly tested in mid-April. Over one year, the stock maintains a gain of nearly 63%.
Olanzapine LAI in Focus Ahead of Annual Publication
The financial calendar sets several concrete dates for the stock. A research and development day is scheduled for May 12, 2026, followed by the publication of annual results on June 16, 2026 (fiscal year April 2025 - March 2026). The general assembly will be held on September 10. During the semi-annual publication covering the period from April to September 2025, the company indicated it expects an acceleration of its revenues in the coming years, driven by Olanzapine LAI. The NDA submitted for this candidate is among the main opportunities identified by the group, alongside the upward revision of the 2025 sales forecasts for UZEDY® by its partner Teva, now expected between $190 and $200 million versus $160 million previously. The company also cited among its risks the dependence on commercialization by Teva and the regulatory uncertainty regarding upcoming approvals. The next concrete appointment remains the R&D day on May 12, followed a month later by the annual accounts.
